Healthcare Industry News: Jazz Pharmaceuticals
News Release - March 9, 2016
Therabron Therapeutics Expands Management TeamROCKVILLE, Md., March 9, 2016 -- (Healthcare Sales & Marketing Network) -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced senior management team appointments. Dr. Alan Cohen has joined Therabron as Senior Vice President and Chief Medical Officer, and Ms. Linda Chang has joined as Senior Vice President and Chief Financial Officer. Both Dr. Cohen and Ms. Chang will report directly to Dr. Thomas F. Miller, Therabron's President and Chief Executive Officer, effective immediately.
Dr. Cohen has been appointed Therabron's Senior Vice President and Chief Medical Officer. Dr. Cohen is a Board Certified Pediatric Pulmonologist with expertise in both acute and chronic lung disorders. Previously, he was Chief Medical Officer at both Eddingpharm USA and Jazz Pharmaceuticals. He also has held executive level R&D leadership positions at Boehringer Ingelheim, InterMune, MAP Pharmaceuticals and MedImmune. Dr. Cohen also maintains an Adjunct Clinical Faculty appointment at Stanford University School of Medicine, where he provides care to pulmonary patients.
Ms. Chang has been appointed Therabron's Senior Vice President and Chief Financial Officer. Prior to joining the company, Ms. Chang served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary at PharmAthene Inc., a NYSE-listed development-stage company. While there, Ms. Chang was responsible for all financial operations including corporate accounting, SEC reporting, tax, treasury, financial planning, investor relations and fundraising. Prior to PharmAthene, Ms. Chang held roles of increasing responsibility in the financial groups at Human Genome Sciences, Booz Allen & Hamilton, Grant Thornton LLC and Otsuka America Pharmaceuticals. She is a Certified Public Accountant.
About Therabron Therapeutics Inc.
At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed. We are a privately held, clinical-stage biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins, which includes the CC10 protein — a molecule with both anti-inflammatory and immunomodulatory mechanisms. Therabron's product candidates have the potential to become first-in-class biologic therapeutics. For additional information, please visit www.therabron.com.
Source: Therabron Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.